Mark Hallman
Radiation Oncology · Philadelphia, PANPI 1124256557
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Boston Scientific at 48.8% of the total. 2024 is the largest year on record at $97, 4.7 times the $21 reported in 2019. That places this record below the midpoint for radiation oncology clinicians in PA, where the typical reported total is $405.
Across 6 payments — averaging $27.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$82
- Siemens Medical Solutions USA, Inc.$44
- Bayer$21
- Myriad Genetic Laboratories, Inc.$21
Across 33 payments — averaging $9180.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$303K
What the payments were for
- Food & beverage$167100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 2 | $82 |
| Siemens Medical Solutions USA, Inc. | 2 | $44 |
| Bayer | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
How this compares
$167 in reported general payments places this provider in the 30th percentile of 339 radiation oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 12 | $32,382 |
| Tamsulosin Hcl | 294 | $6,616 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Philadelphia
- Neil TaunkPhiladelphia$203K
- Wenyin ShiPhiladelphia$119K
- Kevin NeadPhiladelphia$50K
- Adam DickerPhiladelphia$46K
- Tinatin ChabrashviliPhiladelphia$39K
- Bryan PukenasPhiladelphia$36K
- Sameera KumarPhiladelphia$29K
- Joshua MeyerPhiladelphia$25K
- Abigail BermanPhiladelphia$25K
- Michelle Alonso-BasantaPhiladelphia$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.